Peptide Therapeutics Market Size, Share, Trends, Opportunities, Competitive Landscape and Analysis With Compound Annual Growth Rate (CAGR) Of 10.5% By 2027

SEATTLE, April 02, 2021, (PHARMIWEB) — Global Peptide Therapeutics Market – Global Industry Insights

Peptide is a short chain of amino acids, in which amino acids are connected to one another in a sequence by bonds called peptide bonds. Peptides are selective effective signaling molecules, which bind to specific cell surface receptors such as G Protein-Coupled Receptors (GPCRs) or ion channels, where they trigger intracellular effects. Over 7,000 naturally occurring peptides have been identified, which play crucial role in human physiology such as neurotransmitters, hormones, growth factors, ion channel ligands, and anti-infective. Peptides are efficient precursors in designing of novel therapeutics, owing to their specificity, safety, tolerability intrinsic properties and its ability to provide expected results in humans. According to the Bioorganic & Medicinal Chemistry Journal, June 2018, around 60 peptide drugs are approved in the U.S. and in other major markets, such as Europe, and Japan.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1837

Apart from these features, peptides show low production complexity when compared to protein-based biopharmaceuticals, which lowers the production cost. Moreover, peptides find applications in various sectors such as medicine, biotechnology, and therapeutics peptide research. Peptide production requires low production cost and increasing clinical applications are expected to drive growth of the peptide therapeutics market over the forecast period. Global peptide therapeutics market size is forecasted to grow in coming years as peptide based therapeutics has already showed lucrative revenue opportunity to key manufactures, in the past years. For instance, according to the Drug Discovery Today Journal: January 2015, data findings, peptide-based medicine: Lupron from Abbott Laboratories for the treatment of prostate cancer and among others, achieved global sales of more than US$ 2.3 billion in 2011. Moreover, Lantus from Sanofi reached sales of US$ 7.9 billion in 2013.

The global peptide therapeutics market is estimated to account for US$ 23,319.3 Mn in terms of value and is expected to reach US$ 57,166.5 Mn by the end of 2027.

Market Dynamics- Drivers

Increasing Research and Development (R&D) Activities in the Field of Peptide Therapeutics is expected to Drive Peptide Therapeutics Market Growth

Growing increasing research and development (R&D) activities in the field of peptide therapeutics coupled with regulatory approvals to peptide derived drugs or products are expected to drive growth of the global peptide therapeutics market. For instance, according to the Drug Discovery Today Journal data findings, in 2015, the U.S. Food and Drug Administration (FDA) approved over 60 peptide medicines that are available in market with around 140 peptide drugs in clinical trials and over 500 therapeutic peptides in preclinical development. Moreover, increase in the development of novel peptide drugs is expected to drive the market during the forecast period. Glucagon-like peptide-1 (GPL-1) agonists, one of the novel peptide drug class commonly used indicated for the treatment of type 2 diabetes mellitus (T2DM).

Furthermore, growing prevalence of cancer and diabetes among global population is expected to drive the market growth in the near future. Moreover, increasing prevalence of obesity, type 2 diabetes mellitus (T2DM), rising mortality, and increasing demand for replacement of chemotherapy treatment is expected to drive growth of the global peptide therapeutics market over the forecast period. For instance, according to the Cancer Atlas, 2017, an estimated 14.1 million new cancer cases were reported in 2012. According to the National Library of Medicine, 2016, number of people suffering from diabetes is estimated to be 56 million in European region with an overall estimated prevalence of 8.5%, in the same year. In addition to this, India, China and other East and Central Asian countries accounted for nearly half of world’s cancer cases and deaths in 2017. Furthermore, according to the same source, around 19.3 million population is estimated to suffer from cancer and around 11.4 million patients are estimated to die due to cancer by 2025 in emerging economies.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/global-peptide-therapeutics-market-to-surpass-us-450-billion-by-2026-951

Market Dynamics- Restraints

However, low oral availability of peptide drugs since they are administered with injection and poor penetration of the intestinal mucosa is expected to restrain growth of the market in the near future. Peptide drugs are usually administered through injections on a daily basis during long-term treatment and have lesser acceptance in patients than oral administration.

Regional Outlook

Among regions, North America is expected to account for the largest share in the global peptide therapeutics market over the forecast period. This is owing to growing prevalence of chronic diseases such as cancer and rising awareness regarding early detection and treatment of cancer in the region. According to American Cancer Society data findings in 2012, North America accounted for high incidence rate of cancer in children as compared to any other region worldwide. Moreover, according to the same source, in 2012, North America accounted for 13.1% of total estimated cases of cancer worldwide. Furthermore, increasing incidence of diabetes mellitus worldwide is expected to drive the growth of the market. For instance, according to the World Health Organization (WHO), 2016, an estimated 422 million adults are suffering from diabetes. The major spike in incidence of type 2 diabetes over the last decade (2006-2016) is mainly attributed to high prevalence of obesity.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3sJqCHD

Moreover, early diagnosis of cancer increases the survival rate and reduces cancer mortality rate. For instance, in February 2017, World Health Organization (WHO), proposed new guidelines to improve survival rate of people suffering from cancer by ensuring that health service providers are focused on early diagnosis and treatment of disease. WHO proposed three steps to early diagnosis, which include improved public awareness of different cancer symptoms, invest in strengthening and equipping health services and training, and ensuring people living with cancer can access safe and effective treatment. Cancer Research UK organized Early Diagnosis Research Conference in February 2017, to share and discuss latest developments in early diagnosis research.

Competitive Landscape

Key players in the market are focused on various growth strategies such as development of drugs for rare disease and orphan drug, which is expected to drive growth of the global peptide therapeutics market in the near future. For instance, teduglutide, a GLP-2 receptor 2 agonist indicated for treatment of short bowel syndrome and pasireotide, a somatostatin receptor agonist indicated for the treatment of Cushing’s syndrome.

Key players operating in the global peptide therapeutics market include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Co. Ltd., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Encycle Therapeutics, Inc., CirclePharma, Inc., Pfizer Inc., Novartis AG, PeptiDream Inc., and Amgen Inc.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837